Evidence map›Paper›PMID 34003433›Full record

ArticleJournal of clinical immunology2021

Care of Children with DiGeorge Before and After Cultured Thymus Tissue Implantation.

Stephanie E Gupton, Elizabeth A McCarthy, M Louise Markert

2 registry-linked trialsOpen access · hybridAbstract read
In one paragraph

Article in Journal of clinical immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01220531 nacompletednot on this map

Safety and Efficacy of Thymus Transplantation in Complete DiGeorge Anomaly, IND#9836

TypeinterventionalSponsorSumitomo Pharma Switzerland GmbHRan2010 to 2023Enrolled29ConditionsComplete DiGeorge Anomaly, DiGeorge Syndrome, DiGeorge Anomaly, Complete DiGeorge SyndromeArmsCultured Thymus Tissue
NCT02274662 phase4completednot on this map

Expanded Access Protocol Thymus Transplantation for Immunodeficiency, Hematologic Malignancies, and Autoimmune Disease Related to Poor Thymic Function

TypeinterventionalSponsorSumitomo Pharma Switzerland GmbHRan2014 to 2023Enrolled11ConditionsPoor Thymic Function, Immunodeficiency, Athymia, ImmunoreconstitutionArmsCultured Thymus Tissue, Blood Draw, Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Tolerogenic Therapies in Cardiac Transplantation.International journal of molecular sciences · 2025
    Review
  5. Impact of newborn screening for SCID on the management of congenital athymia.The Journal of allergy and clinical immunology · 2024
    Article
  6. Congenital Athymia: Unmet Needs and Practical Guidance.Therapeutics and clinical risk management · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Stephanie E GuptonDepartment of Pediatrics, Division of Allergy and Immunology, Duke University Medical Center, Durham, NC, USA. stephanie.gupton@duke.edu.ORCID 0000-0002-4222-4622
Elizabeth A McCarthyDepartment of Pediatrics, Division of Allergy and Immunology, Duke University Medical Center, Durham, NC, USA.
M Louise MarkertDepartment of Pediatrics, Division of Allergy and Immunology, Duke University Medical Center, Durham, NC, USA.
Duke Medical Center · USDuke University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChildren with complete DiGeorge anomaly (cDGA) have congenital athymia plus a myriad of other challenging clinical conditions. The term cDGA encompasses children with congenital athymia secondary to 22q11.2DS, CHARGE syndrome (coloboma, heart defects, choanal atresia, growth or mental retardation, genital abnormalities, and ear abnormalities and/or deafness), and other genetic abnormalities. Some children have no known genetic defects. Since 1993, more than 100 children with congenital athymia have been treated with cultured thymus tissue implantation (CTTI). Naïve T cells develop approximately 6 to 12 months after CTTI. Most of the children had significant comorbidities such as heart disease, hypoparathyroidism, and infections requiring complex clinical care post cultured thymus tissue implantation (CTTI).

objectiveThe purpose of this guidance is to assist multidisciplinary teams in caring for children with cDGA both before and after CTTI.

methodsThirty-one specialists, in addition to the authors, were asked to share their experience in caring for children with cDGA at Duke University Health System, before and after CTTI. These specialists included physicians, nurses, dentists, therapists, and dieticians.

resultsThe goal of a multidisciplinary approach is to have children in the best possible condition for receiving CTTI and provide optimal care post CTTI through development of naïve T cells and beyond. The CTT (cultured thymus tissue) must be protected from high doses of steroids which can damage CTT. Organs must be protected from adverse effects of immunosuppression.

conclusionCreating a multidisciplinary team and a detailed plan of care for children with cDGA is important for optimal outcomes.

Indexed as

Anti-Infective AgentsBacterial InfectionsChildDiGeorge SyndromeHumansImmunizationMycosesPractice Guidelines as TopicThymus GlandTissue Culture TechniquesAnti-Infective Agents22q11.2 deletion syndromeCHARGE syndromeComplete DiGeorge anomalyCongenital athymiaCultured thymus tissue implantation

Identifiers

PMID34003433
PMCPMC8249267
OpenAlexW3161644829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.